SECsense Logo

AstraZeneca PLC 6-K Report: Capital Group's Shareholding Update - August 2025

$AZN
Form 6-K
Filed on: 2025-08-21
Source
AstraZeneca PLC 6-K Report: Capital Group's Shareholding Update - August 2025

Key Information from the Financial Report (Form 6-K) - AstraZeneca PLC

  1. Company Details
  • Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom
  • SEC File Number: 001-11960
  • Form Submitted: 6-K (Report of Foreign Issuer)
  1. Reporting Period
  • For the Month: August 2025
  1. Shareholder Notification
  • Person Subject to Notification Obligation: The Capital Group Companies, Inc.
  • Registered Office Location: Los Angeles, USA
  1. Reason for Notification
  • The notification is due to an acquisition or disposal of voting rights.
  1. Details of Holdings
  • Voting Rights Held:
    • Percentage of voting rights: 4.997854%
    • Total number of voting rights held: 77,500,852
  • Previous Notification Position:
    • Percentage of voting rights previously reported: 5.009591%
  • Date Threshold Crossed: August 19, 2025
  • Date Issuer Notified: August 20, 2025
  1. Types of Shares Held
  • Common Stock (ISIN: GB0009895292):
    • Direct Voting Rights: 62,815,312
    • Percentage of Direct Voting Rights: 4.050817%
  • Depository Receipts (ISIN: US0463531089):
    • Indirect Voting Rights: 14,685,540
    • Percentage of Indirect Voting Rights: 0.947037%
  1. Total Voting Rights
  • Total Voting Rights: 77,500,852
  • Resulting percentage of total voting rights: 4.997854%
  1. Additional Information
  • The Capital Group Companies, Inc. does not own shares for its account; the shares are owned by accounts under the discretionary management of its investment management companies.
  • The detailed structure includes several affiliates and subsidiaries involved in investment management.
  1. Signature
  • Signed By: Matthew Bowden, Company Secretary
  • Date of Signature: August 21, 2025

Insights

  • Shareholder Activity: The Capital Group Companies, Inc. has slightly decreased its shareholding in AstraZeneca, dropping just below the previously reported threshold of 5%.
  • Regulatory Compliance: The report is consistent with the regulations under the Securities Exchange Act of 1934, reflecting transparency in shareholder voting rights.
  • Investment Management Structure: The Capital Group Companies' extensive network of investment management companies indicates a robust infrastructure for managing assets and reflects institutional investor confidence in AstraZeneca.

This report provides crucial insights into the shareholder structure and voting power dynamics within AstraZeneca, important for analysts tracking shareholder influence on corporate governance and potential changes in strategic directions.